Autosomal dominant spastic paraplegia type 37

Autosomal dominant spastic paraplegia type 37 (SPG37) is a rare hereditary spastic paraplegia characterized by progressive weakness and spasticity (stiffness) of the lower limbs. It was mapped to chromosome 8p21.1-q13.3 and has been described in a single large North American family. The condition primarily affects the corticospinal tracts of the central nervous system, which are the nerve pathways responsible for voluntary movement of the legs. Patients typically develop a slowly progressive gait disturbance due to increasing leg stiffness and weakness, which can lead to significant difficulty walking over time. SPG37 is classified as a "pure" or "uncomplicated" form of hereditary spastic paraplegia, meaning that the primary clinical features are limited to lower limb spasticity and weakness, with hyperreflexia (exaggerated reflexes) and extensor plantar responses (Babinski sign), without significant additional neurological involvement such as cognitive decline, ataxia, or peripheral neuropathy. The age of onset in the reported family was variable, ranging from childhood to adulthood. The causative gene for SPG37 has not yet been definitively identified, though the chromosomal locus has been established. Diagnosis is based on clinical evaluation, family history consistent with autosomal dominant inheritance, and exclusion of other causes of spastic paraplegia. There is currently no cure or disease-modifying treatment for SPG37. Management is symptomatic and supportive, focusing on physical therapy to maintain mobility and reduce spasticity, antispasticity medications such as baclofen or tizanidine, and assistive devices as needed. Regular follow-up with a neurologist is recommended to monitor disease progression.

Common questions about Autosomal dominant spastic paraplegia type 37